Voya Investment Management LLC Acquires 20,498 Shares of Progyny, Inc. $PGNY

Voya Investment Management LLC lifted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 9.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,833 shares of the company’s stock after acquiring an additional 20,498 shares during the period. Voya Investment Management LLC’s holdings in Progyny were worth $5,097,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Cetera Trust Company N.A raised its stake in shares of Progyny by 303.1% in the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after purchasing an additional 985 shares during the last quarter. Militia Capital Partners LP grew its holdings in Progyny by 100.0% during the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock worth $45,000 after buying an additional 1,000 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Progyny in the 2nd quarter valued at $77,000. AlphaQuest LLC lifted its stake in Progyny by 57.9% during the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company’s stock valued at $127,000 after acquiring an additional 2,079 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Progyny by 203.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after acquiring an additional 4,708 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Canaccord Genuity Group increased their target price on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a report on Monday, November 17th. Barclays started coverage on shares of Progyny in a research report on Monday, December 8th. They issued an “overweight” rating and a $29.00 price objective for the company. Wall Street Zen lowered shares of Progyny from a “buy” rating to a “hold” rating in a research note on Saturday, December 20th. KeyCorp upgraded Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 target price on the stock in a research note on Tuesday, November 11th. Finally, JPMorgan Chase & Co. upped their target price on Progyny from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $27.50.

Insider Buying and Selling at Progyny

In other Progyny news, CEO Peter Anevski purchased 79,500 shares of the stock in a transaction dated Thursday, November 13th. The shares were bought at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the transaction, the chief executive officer directly owned 680,251 shares in the company, valued at approximately $16,523,296.79. This trade represents a 13.23% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 22,046 shares of company stock valued at $561,691 in the last quarter. 9.40% of the stock is owned by corporate insiders.

Progyny Stock Down 0.2%

Shares of PGNY stock opened at $25.52 on Friday. The firm has a market cap of $2.20 billion, a P/E ratio of 40.50, a PEG ratio of 2.01 and a beta of 0.97. The company has a 50 day moving average of $23.50 and a 200-day moving average of $22.67. Progyny, Inc. has a 12-month low of $14.32 and a 12-month high of $27.76.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.39 by $0.06. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. Progyny’s revenue for the quarter was up 9.3% on a year-over-year basis. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. As a group, equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current year.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.